Pfizer’s respiratory syncytial virus (RSV) vaccine Abrysvo has shown efficacy in immunocompromised adults, the pharma announced Monday. In substudy B of Pfizer’s ongoing Phase 3 MONeT trial, Abrysvo ...
As China's aging population increases demand for therapies treating everything from cancer and diabetes to dementia, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback